Company Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases

[Business Wire] – Vertex Pharmaceuticals Incorporated and Parion Sciences today announced that the companies will collaborate to develop investigational epithelial sodium channel inhibitors for the potential treatment of cystic fibrosis and other pulmonary . . . → Read More: Company Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases Similar Articles: Stock Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Vertex to Present at the UBS Healthcare Conference on May 19 Company Update (NASDAQ:VRTX): Vertex Reports First Quarter 2015 Financial Results Stock Update (NASDAQ:VRTX): Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation